<DOC>
	<DOCNO>NCT00002972</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient unresectable stage IIIB , stage IV recurrent lung cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess therapeutic activity paclitaxel patient bronchoalveolar carcinoma ( BAC ) . - Assess duration response patient present objective response . - Characterize acute side effect paclitaxel patient BAC . - Assess role biological parameter natural history response therapy BAC ; evaluate expression Ki67 , p53 , K-ras mutation . OUTLINE : This open label , nonrandomized , multicenter study . Paclitaxel administer every 3 week 3 hour continuous infusion dextrose normal saline . Patients treat minimum 2 cycle unless serious toxicity complication occur . Disease assess every 6 week document progression ; treatment side effect assess separately cycle therapy . Treatment give maximum 6 cycle therapy disease progression , unacceptable toxicity , patient refusal occur . PROJECTED ACCRUAL : 16 25 patient accrue .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove bronchoalveolar carcinoma ( BAC ) base criterion : Absence primary adenocarcinoma elsewhere Absence demonstrable central bronchogenic origin A peripheral location lung parenchyma Intact interstitial framework lung A histological appearance set apart tumor , characteristic pattern growth : cuboidal cylindrical cell line alveolar septum preservation basic pulmonary architecture Must unresectable Stage IIIB , IV , recurrent BAC Evidence multinodular lesion involve lung bilaterally unilaterally ( latter lesion must involve one lobe ) At least one target lesion bidimensionally measurable undergone prior irradiation No CNS disease PATIENT CHARACTERISTICS : Age : 18 75 ( inclusive ) Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : ANC least 1,500/mm^3 Hepatic : Bilirubin le 2 time upper limit normal SGOT , SGPT , alkaline phosphatase less 2 time upper limit normal Renal : Creatinine le 1.5 time upper limit normal Cardiovascular : No history ischemic congestive heart disease No arrhythmia require chronic cardiopulmonary medication No history clinically electrographically document myocardial infarction Other : No preexist motor serious sensory neurotoxicity No active prior second primary cancer except basal cell carcinoma skin carcinoma situ cervix No clinical evidence uncontrolled infection Not pregnant nursing Negative pregnancy test 72 hour prior start study medication Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy Must least one bidimensional lesion outside irradiated field Surgery : Fully recover prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>